

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The prevalence and associated factors of preterm birth in Ethiopia: Systematic review and meta-analysis protocol

| | |
|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2019-035574 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 06-Nov-2019 |
| Complete List of Authors: | Muchie, Kindie Fentahun; Bahir Dar University, Epidemiology and Biostatistics Molla, Ayenew; University of Gondar College of Medicine and Health Sciences, Epidemiology and Biostatistics; Teshome, Destaw; University of Gondar College of Medicine and Health Sciences, Epidemiology and Biostatistics Yenit, Melaku; University of Gondar, Epidemiology and Biostatistics Sisay, Malede; University of Gondar College of Medicine and Health Sciences, Epidemiology and Biostatistics Mekonnen, Fantahun Ayenew ; University of Gondar, Epidemiology and Biostatistics Habitu, Yohanes Ayanaw; University of Gondar, Reproductive Health |
| Keywords: | EPIDEMIOLOGY, PUBLIC HEALTH, STATISTICS & RESEARCH METHODS |
| | |

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The prevalence and associated factors of preterm birth in Ethiopia: Systematic review and meta-analysis protocol

Kindie Fentahun Muchie^{1*}, Melaku Kindie Yenit², Destaw Fetene Teshome², Ayenew Molla Lakew², Malede Mekuanint Sisay², Fantahun Ayenew Mekonnen², Yohanes Ayanaw Habitu³

¹Department of Epidemiology and Biostatistics, School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia

²Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

³Department of Reproductive Health, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

E-mail addresses:

KFM (mkindief@gmail.com), MKY (melaku98@gmail.com), DFT (destaw.fetene@gmail.com), AML (mayenew15@gmail.com), MMS (maledecsa@gmail.com), FAM (fantahun.ayenew@yahoo.com), YAH (ayanawyohanes@yahoo.com)

*Correspondence

ABSTRACT

Introduction: Preterm birth complications are the leading cause of death among neonates globally. The reduction in neonatal mortality is not remarkable in Ethiopia. Therefore, this review is aimed at assessing the magnitude and associated factors of preterm birth in Ethiopia.

Methods and analysis: The preferred reporting items for systematic reviews and meta-analyses guideline will be followed during the systematic review. We will include all observational studies published from Jan 01, 2009 to Dec 31, 2019 that examined the level and/or associated factors of preterm birth in Ethiopia. Electronic databases such as PubMed, and Science Direct as well as Google search engine and Google Scholar will be searched. The pooled prevalence of preterm and effect size of association for associated factors will be analyzed using the Stata software version 14. The heterogeneity between studies will be measured by I^2 statistics. A random-effects model will be used to estimate if heterogeneity detected among studies. Publication bias will be assessed using a funnel plot. Forest plots will be used to present the combined estimate with 95% confidence intervals. The quality of evidence of the outcomes will be assessed with the GRADE approach.

Ethics and dissemination: No ethical approval is necessary for a systematic review. The findings will be published in a peer-reviewed journal.

PROSPERO registration number: CRD42017077356.

Keywords: Preterm birth, Prevalence, Associated Factors, Ethiopia, Systematic review, Meta-analysis

STRENGTHS AND LIMITATIONS OF THIS STUDY

- The proposed systematic review focuses on preterm birth, the global leading cause of neonatal mortality, in Ethiopia where the reduction in neonatal mortality is not remarkable
- This proposed systematic review and meta-analysis will provide updated knowledge on the prevalence of preterm birth in Ethiopia.
- The proposed systematic review with meta-analysis will provide a comprehensive knowledge on the associated factors of preterm birth in Ethiopia.
- The preferred reporting items for systematic reviews and meta-analyses (PRISMA) guideline will be followed during the proposed systematic review.
- Standard tool for critical appraisal and data extraction will be used
- Only quantitative observational studies published in English will be included.

INTRODUCTION

Preterm birth is a birth before 37 completed weeks of gestation (1). It is more prevalent in Africa and Asia. Preterm birth complications remained the leading cause of under-5 and neonatal mortalities. Preterm birth, the majority being spontaneously, occurs for a variety of reasons(2). Currently, World Health Organization (WHO) is committed to reduce the health problems and lives lost as a result of preterm births.

Globally, 14.9 million babies born preterm making a birth rate of 11.1%, ranging from 5% to 18%, in 2010 (3). The majority (60%) of these births occurred in sub-Saharan Africa and South Asia where 52% of global livebirths occur. The estimated global preterm birth rate was also 10.6%, 14.84 million live preterm births, in 2014 (4). Twelve million (81.1%) of these preterm births occurred in Asia and sub-Saharan Africa (4) showing the contribution is raised from 2010. Ethiopia is one of the low-middle incomes countries in Sub-Saharan Africa.

Preterm birth remains a crucial issue in child mortality and improving quality of maternal and newborn care(4). Complications of preterm birth is the leading cause of death among under 5 children with risk of dying ranged between 1.9 and 155.1 per 1,000 livebirths , in 2015 (5). In the same report, it had been found as the leading cause of death among neonates contributing for 0.944 million deaths. Complication of infants born preterm result in significant cost to the health sector, parents and the society in that preterm neonates take the first place for neonatal intensive care unit (NICU) admission and longer hospital stay globally (4).

Currently, WHO is committed to reduce the health problems and lives lost as a result of preterm births (6). Hence, WHO had developed new guidelines including interventions

1
2
3 provided to the mother and the newborn baby (6). The Every Woman Every
4 Child movement is also aiming to intensify national and international commitment and
5 action to ensure that women, children and adolescents are at the heart of development.
6
7
8
9
10 The movement puts into action the global strategy (2016-2030) (7). The strategy is aimed
11 to end all preventable deaths of women, children and adolescents within a generation
12 and ensuring their well-being. Though Ethiopia achieved the millennium development
13 goal 4 with 67% under-five mortality reduction from the 1990 estimate, the reduction in
14 neonatal mortality is not remarkable (8). However, Ethiopia has planned to reduce
15 neonatal mortality rate from 28 in 2015/16 to 10 by 2019/2020 (9). Furthermore, the
16 country is also devoted to end preventable deaths of newborns and children under 5 years
17 of age by 2030 (10).
18
19
20
21
22
23
24
25
26
27

28 There are local studies on preterm conducted in Ethiopia. The need for an accurate and
29 reliable result (11, 12), a single study aggregating these studies is necessary for policy
30 makers and implementers. Even though, there is a systematic review (13) done, it
31 addressed only the effect of pregnancy induced hypertension and multiple pregnancies
32 on preterm birth. However, literatures show that more factors affect preterm birth. Some
33 of the identified associated factors of preterm birth in Ethiopia are pregnancy induced
34 hypertension (14, 15), chronic illness (14, 16), obstetric complication (17), nutritional
35 status (17), anemia (16), antenatal care follow up (15-17), substance intake during
36 pregnancy (18), history of abortion (18), history of still birth (18), premature rupture of
37 membrane (16, 18), hypertension during pregnancy (18), multiple gestation (15, 18),
38 history of low birth weight (18), history of preterm birth (18), and income status (16).
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Hence, conducting a systematic review and meta-analysis on preterm birth is paramount important in Ethiopia by updating the latest possible evidences.

Therefore this review is aimed at assessing the magnitude and associated factors of preterm birth among in Ethiopia.

METHODS AND ANALYSIS

Development of the review method

The methods of this systematic review and meta-analysis protocol was developed based on the PRISMA Protocols (PRISMA-P) 2015 statement (19). The preferred reporting items for systematic reviews and meta-analyses (PRISMA) guideline will be followed during the systematic review(20, 21). The result of the review will be reported according to the PRISMA guideline for reporting (22). The four phases that were drawn from the PRISMA flow chart (23) will be documented in the results to show the study selection process from initially identified records to finally included studies. The protocol for this systematic review and meta-analysis is registered in international prospective register of systematic reviews (PROSPERO) and obtained the registration number (CRD42017064585).

Eligibility criteria

We will include all observational studies that examined the level and/or associated factors of preterm birth in Ethiopia. Reviews, editorials, case series and case reports on preterm birth as well as studies that only reported qualitative findings on preterm birth will be excluded. In studies that reported both quantitative and qualitative results, we will only consider the quantitative findings. Studies will be considered relevant if they assessed the magnitude of preterm birth and/or examined the associated factors of preterm birth.

Search strategy

Major medical electronic databases such as PubMed, and Science Direct will be searched to identify relevant literature for the review. To cover grey literature, we will hand-search literature using the Google search engine and Google Scholar and references of electronically identified articles. Further, references list will also be considered from relevant studies considered for critical appraisal.

The literature search will be carried out by the primary author (KFM). The search will be limited to humans, and journal studies published in English from Jan 01, 2009 to Dec 31, 2020. We will apply Medical Subject Headings (MeSH) terms from PubMed, and combined key words to identify studies in the databases.

Accordingly, literatures will be retrieved using the exact search phrase (*"Premature Birth/epidemiology"[Mesh] OR "Premature Birth/etiology"[Mesh] OR "Premature Birth/statistics and numerical data"[Mesh] OR premature birth* [MeSH] OR preterm birth OR premature birth OR preterm labo* OR preterm deliver* OR preterm infant OR preterm neonate* OR preterm newborn* OR birth outcome OR pregnancy outcome\$ OR pregnancy complication\$ OR birth outcome\$ OR birth complication\$) AND Ethiopia AND ((incidence OR prevalence OR magnitude OR burden) OR (predict* OR associated factor* OR risk factor* OR determinant*))*) from PubMed. This will be customized for other databases.

Study selection process

The retrieved studies will be exported to the citation manager (EndNote) and then duplicates excluded. The titles and abstracts of the studies will be reviewed for screening by two authors (KFM and AML) for obvious exclusion according to the inclusion criteria.

1
2
3 Based on this screening, the titles and abstracts of the studies will be classified as
4 included, excluded, and undecided. Full text of all the included and the undecided studies
5 will be searched for further eligibility assessment.
6
7

8
9
10 The full texts of the included and undecided categories of the studies will be independently
11 reviewed by two authors (KFM and AML) against the eligibility criteria for final inclusion.
12

13
14 Studies that are not eligible based on the examination of the full-text will be excluded by
15 stating the reasons according to the inclusion criteria. Disagreements between the two
16 reviewers will be resolved through discussion and consensus.
17
18

19
20 Studies deemed to be appropriate will be scanned in full to determine relevance.
21

22
23 Secondly, the references lists of all relevant studies will be reviewed to find additional
24 studies that may have been difficult to detect in the database search due to non-reporting
25 in the abstract (possibly due to non-significant effects). Studies published by the same
26 team will be carefully reviewed to ensure the results of a given study are not included
27 twice in this review.
28
29
30
31
32
33

34 35 **Critical appraisal**

36
37 All of the included studies will be critically appraised for their validity. The three authors
38 (DFT, MKY, FA) will check the methodological robustness and validity of the findings
39 using the Joanna Briggs Institute (JBI) Meta-Analysis of Statistics Assessment and
40 Review Instrument (24). Uncertainties will be resolved by joint discussion between the
41 reviewers. Disagreements among the reviewers will be resolved through discussion and
42 consensus.
43
44
45
46
47
48
49

50
51 The JBI Meta-Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI)
52 will be used for critical appraisal (25). This tool contains a separate appraisal checklist for
53
54
55
56
57

1
2
3 each type of the study design. The reviewers will independently assess articles prior to
4 inclusion in the final review using this instrument. Any disagreement among the reviewers
5 will be resolved through discussion, and by involving another reviewer. A Study with
6 quality assessment score of 50% and above and a study having a response rate of 80%
7 and above were included in the final review.
8
9

14 **Data extraction**

15
16 The JBI data extraction form will be used to extract the characteristics of the studies and
17 prevalence of preterm birth (primary outcome) as well as Odds ratio (secondary
18 outcomes). A standardized excel sheet will be created and information from the
19 standardized review forms will be transferred in order to be readily available for the
20 systematic review. Three reviewers (KFM, MMS and AML) will extract data
21 independently. Disagreements among the reviewers were resolved through discussion
22 and consensus.
23
24
25
26
27
28
29
30
31
32

33 This tool will include information on the author, year of publication, objective, study
34 setting, year of survey, study design, sample size, data collection method, study
35 participants, definition used for preterm birth, prevalence of preterm, 95% CI for
36 prevalence of preterm birth, and list of associated factors with their effect size. A
37 quantitative data of cross-tabulation between the subject's characteristics (associated
38 factors) and the preterm birth will also systematically abstracted.
39
40
41
42
43
44
45

46 **Data synthesis and statistical analysis**

47
48 The individual studies will be concisely described using a summary table. The summary
49 table particularly describes the characteristics of the included studies and the main
50 findings.
51
52
53
54
55
56
57

1
2
3 The data will be analyzed by the Stata software version 14. For studies which did not
4 present a standard error (SE), it will be calculated using the formula; $SE = \sqrt{(p \times (1-p)/n)}$.
5
6 The calculated standard error and prevalence rate of each study will then entered into
7
8 Stata software to calculate the overall prevalence and its 95% confidence interval (CI).
9
10 Similarly, the relationship between factors and preterm birth will be summarized using
11
12 statistical estimates of effect sizes, odds ratio.
13
14

15
16 The level of heterogeneity among the studies will be quantified using the I^2 statistics (26).
17
18 Meta-analysis using random effects model will be conducted for the I^2 value of more than
19
20 75%, considered as heterogeneity. Publication bias will be assessed using a funnel plot.
21
22 Subgroup analysis will be sought based on possible characteristics of the studies. Forest plots
23
24 will be used to present the combined estimate with 95% CI. The quality of evidence of the
25
26 outcomes will be assessed with the GRADE approach. If no more than one study will be
27
28 found for each of the objective, then the finding will be synthesized narratively.
29
30
31

32 **Potential limitations**

33
34 Only quantitative observational studies published in English will be included. This might
35
36 excluded studies those published in other languages. Further, qualitative studies that may
37
38 assessed the associated factors might be excluded. Therefore, the readers are advised
39
40 to take this into account.
41
42
43

44 **Patient and public involvement**

45
46 It was not appropriate to involve patients or the public in the design, or conduct, or
47
48 reporting, or dissemination plans of our research as no individual information will be
49
50 discussed.
51
52
53

54 **Ethics and dissemination**

1
2
3 The review will be based on published data, and thus there is no requirement for ethical
4 approval. The results will be disseminated through publication in a peer reviewed journal,
5
6 and through presentations at academic conferences.
7
8

9 10 **DISCUSSION**

11
12 It is crucial to know the importance of preterm birth and contributing factors considering
13 the latest statistics in a country. Hence, this review will present on the country wide
14 magnitude of preterm birth and the associated factors of preterm birth. The result will
15 provide information to guide health professionals and health policy makers for monitoring
16 preterm birth strategy and applying necessary preventive and appropriate measures to
17 decrease preterm birth.
18
19
20
21
22
23
24
25

26 **Abbreviations**

27
28 ACTION: Antenatal Corticosteroids for Improving Outcomes in preterm Newborns

29
30 CI: Confidence Interval

31
32 JBI: Joanna Briggs Institute

33
34 JBI-MASARI: JBI Meta-Analysis of Statistics Assessment and Review Instrument

35
36 KMC: Kangaroo Mother Care

37
38 LMICs: Low and Middle Income Countries

39
40 MeSH: Medical Subject Headings

41
42 NICU: Neonatal Intensive Care Unit

43
44 NMR: Neonatal Mortality Rate

45
46 PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analyses

47
48 PRISMA-P: Preferred Reporting Items for Systematic Reviews and Meta-analyses
49
50
51
52
53
54 Protocol

PROSPERO: Prospective Register of Systematic Reviews

SE: Standard Error

WHO: World Health Organization

Declarations

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Competing interests

The authors declare that they have no competing interests

Funding

None.

Author contributions

KFM, MKY, YAH contributed to the conception of the research protocol. KFM, AML, DFT, MMS, FAM designed the study. KFM, DFT, AML reviewed the literature, and wrote the protocol. KFM, AML, DFT, MKY, FAM, MMS, and YAH reviewed and rewrote the protocol. All authors read and approved the final manuscript.

References

1. Who: Recommended Definitions, Terminology and Format for Statistical Tables Related to The Perinatal Period And Use of A New Certificate For Cause of Perinatal Deaths. *Acta obstetricia et gynecologica Scandinavica*. 1977;56(3):247-53.
2. March of Dimes, PMNCH, Save the Children, WHO. Born Too Soon: The Global action report on preterm Birth. In: Eds CP Howson, MV Kinney, JE Lawn, editors. Geneva: World Health Organization; 2012.

3. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller A-B, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. *The Lancet*. 2012;379(9832):2162-72.
4. Chawanpaiboon S, Vogel JP, Moller A-B, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. *The Lancet Global Health*. 2019;7(1):e37-e46.
5. Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. *The Lancet*. 2016;388(10063):3027-35.
6. WHO. WHO Fact sheets on Preterm birth In: WHO, editor. 2018.
7. Every Woman Every Child. The global strategy for women's, children's, and adolescents' health (2016-2030): Survive, thrive, transform. In: Every Woman Every Child, editor. 2015.
8. Ruducha J, Mann C, Singh NS, Gemebo TD, Tessema NS, Baschieri A, et al. How Ethiopia achieved Millennium Development Goal 4 through multisectoral interventions: a Countdown to 2015 case study. *The Lancet Global Health*. 2017;5(11):e1142-e51.
9. The Federal Democratic Republic of Ethiopia Ministry of Health. Health Sector Transformation Plan. 2015.
10. United Nations. Sustainable Development Goals. Secretary-General. 2015.
11. Cohn LD, Becker BJ. How meta-analysis increases statistical power. *Psychological Methods*. 2003;8(3):243-53.
12. Noble JH, Jr. Meta-analysis: Methods, strengths, weaknesses, and political uses. *The Journal of Laboratory and Clinical Medicine*. 2006;147(1):7-20.
13. Mulualem G, Wondim A, Woretaw A. The effect of pregnancy induced hypertension and multiple pregnancies on preterm birth in Ethiopia: a systematic review and meta-analysis. *BMC research notes*. 2019;12(1):91.
14. Gebreslasie K. Preterm Birth and Associated Factors among Mothers Who Gave Birth in Gondar Town Health Institutions. *Advances in Nursing*. 2016;2016.

15. Teklay G, Teshale T, Tasew H, Mariye T, Berihu H, Zeru T. Risk factors of preterm birth among mothers who gave birth in public hospitals of central zone, Tigray, Ethiopia: unmatched case–control study 2017/2018. *BMC research notes*. 2018;11(1):571.
16. Bekele T, Amanon A, Gebreslasie KZ. Preterm birth and associated factors among mothers who gave birth in Debremarkos-town health institutions 2013 institutional basedcrosssectional study. *Gynecology & Obstetrics (Sunnyvale)* 2015;5(5).
17. Mekonen DG, Yismaw AE, Nigussie TS, Ambaw WM. Proportion of Preterm birth and associated factors among mothers who gave birth in Debretabor town health institutions, northwest, Ethiopia. *BMC research notes*. 2019;12(1):2.
18. Bekele I, Demeke T, Dugna K. Prevalence of Preterm Birth and its Associated Factors among Mothers Delivered in Jimma University Specialized Teaching and Referral Hospital, Jimma Zone, Oromia Regional State, South West Ethiopia. *Journal of Women's Health Care*. 2017;6(1).
19. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews*. 2015;4(1).
20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151.
21. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Reprint—preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Physical therapy*. 2009;89(9):873-80.
22. Beller E, Glasziou P, Altman D, Hopewell S, Bastian H, Chalmers I, et al. PRISMA for abstracts: reporting systematic reviews in journal and conference abstracts. *PLoS Med*. 2013;10(4).
23. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7).
24. Joanna Briggs institute Reviewers' manual 2014 edition. Adelaide: Adelaide University; 2014.
25. Joanna Briggs institute reviewers' manual 2008.
26. Higgins J, Hompson S. Quantifying heterogeneity in a meta-analysis 2002.

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

| Section and topic | Item No | Checklist item | (Page No.#) |
|-----------------------------------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| ADMINISTRATIVE INFORMATION | | | |
| Title: | | | |
| Identification | 1a | Identify the report as a protocol of a systematic review | 1 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | NA |
| Registration | 2 | If registered, provide the name of the registry (such as PROSPERO) and registration number | 2, 6 |
| Authors: | | | |
| Contact | 3a | Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author | 1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | 12 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | NA |
| Support: | | | |
| Sources | 5a | Indicate sources of financial or other support for the review | 12 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | NA |
| Role of sponsor or funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | NA |
| INTRODUCTION | | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | 4-5 |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | 6 |
| METHODS | | | |
| Eligibility criteria | 8 | Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review | 6 |
| Information sources | 9 | Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage | 7 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | 7 |

| | | | |
|------------------------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Study records: | | | |
| Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | 6-10 |
| Selection process | 11b | State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) | 6-9 |
| Data collection process | 11c | Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | 9 |
| Data items | 12 | List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications | 9 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | 9 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | 8-9 |
| Data synthesis | 15a | Describe criteria under which study data will be quantitatively synthesised | 10 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's τ) | 10 |
| | 15c | Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) | 10 |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned | 10 |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) | 10 |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (such as GRADE) | 10 |

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

The prevalence and associated factors of preterm birth in Ethiopia: Systematic review and meta-analysis protocol

| | |
|---------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2019-035574.R1 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 20-Feb-2020 |
| Complete List of Authors: | Muchie, Kindie Fentahun; Bahir Dar University, Epidemiology and Biostatistics Molla, Ayenew; University of Gondar College of Medicine and Health Sciences, Epidemiology and Biostatistics; Teshome, Destaw; University of Gondar College of Medicine and Health Sciences, Epidemiology and Biostatistics Yenit, Melaku; University of Gondar, Epidemiology and Biostatistics Sisay, Malede; University of Gondar College of Medicine and Health Sciences, Epidemiology and Biostatistics Mekonnen, Fantahun Ayenew ; University of Gondar, Epidemiology and Biostatistics Habitu, Yohanes Ayanaw; University of Gondar, Reproductive Health |
| Primary Subject Heading: | Epidemiology |
| Secondary Subject Heading: | Public health, Global health, Epidemiology |
| Keywords: | EPIDEMIOLOGY, PUBLIC HEALTH, STATISTICS & RESEARCH METHODS |
| | |

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 1 **The prevalence and associated factors of preterm birth in Ethiopia: Systematic**
4 **review and meta-analysis protocol**

5
6 3 Kindie Fentahun Muchie^{1*}, Ayenew Molla Lakew², Destaw Fetene Teshome², Melaku
7
8 4 Kindie Yenit², Malede Mequanent Sisay², Fantahun Ayenew Mekonnen², Yohanes
9
10 5 Ayanaw Habitu³
11
12 6

13
14 7 ¹Department of Epidemiology and Biostatistics, School of Public Health, College of Medicine and
15
16 8 Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia

17
18 9 ²Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and
19
20 10 Health Sciences, University of Gondar, Gondar, Ethiopia

21
22 11 ³Department of Reproductive Health, Institute of Public Health, College of Medicine and Health
23
24 12 Sciences, University of Gondar, Gondar, Ethiopia
25

26
27 14 **E-mail addresses:**

28
29 15 KFM (mkindief@gmail.com), AML (mayenew15@gmail.com), DFT
30
31 16 (destaw.fetene@gmail.com), MKY (melaku98@gmail.com), MMS
32
33 17 (maledecsa@gmail.com), FAM (fantahun.ayenew@yahoo.com), YAH
34
35 18 (ayanawyohanes@yahoo.com)
36
37 19

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

19 ***Correspondence**

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

1 **ABSTRACT**

2 **Introduction:** Preterm birth complications are the leading cause of death among
3 neonates globally. The reduction in neonatal mortality is not remarkable in Ethiopia.
4 Therefore, this review is aimed at assessing the magnitude and associated factors of
5 preterm birth in Ethiopia.

6 **Methods and Analysis:** The preferred reporting items for systematic reviews and meta-
7 analyses guideline will be followed during the systematic review. We will include all
8 observational studies published from Jan 01, 2009 to Dec 31, 2019 that examined the
9 level and/or associated factors of preterm birth in Ethiopia. Electronic databases such as
10 PubMed, and Science Direct as well as Google search engine and Google Scholar will
11 be searched. The pooled prevalence of preterm and effect size of association for
12 associated factors will be analyzed using the Stata software version 14. The
13 heterogeneity between studies will be measured by I^2 statistics. A random-effects model
14 will be used to estimate if heterogeneity detected among studies. Publication bias will be
15 assessed using a funnel plot. Forest plots will be used to present the combined estimate
16 with 95% confidence intervals. The quality of evidence of the outcomes will be assessed
17 with the GRADE approach.

18 **Ethics and dissemination:** No ethical approval is necessary for this systematic review.
19 The findings will be published in a peer-reviewed journal.

20 **PROSPERO registration number:** CRD42017077356.

21 **Keywords:** Preterm birth, Prevalence, Associated Factors, Ethiopia, Systematic review,
22 Meta-analysis

1 STRENGTHS AND LIMITATIONS OF THIS STUDY

- 2 ➤ The proposed study will provide updated knowledge on the prevalence of preterm
3 birth, leading cause of neonatal death, in Ethiopia where reduction in neonatal
4 mortality is no remarkable.
- 5 ➤ The proposed study will provide a comprehensive knowledge on the associated
6 factors of preterm birth in Ethiopia.
- 7 ➤ The PRISMA guideline will be followed during the proposed systematic review.
- 8 ➤ Standard tool for critical appraisal and data extraction will be used
- 9 ➤ Only quantitative observational studies published in English will be included.

1 INTRODUCTION

2 Preterm birth is a birth before 37 completed weeks of gestation (1). It is more prevalent
3 in Africa and Asia. Preterm birth complications remained the leading cause of under-5
4 and neonatal mortalities. Preterm birth, the majority being spontaneously, occurs for a
5 variety of reasons(2). Currently, World Health Organization (WHO) is committed to reduce
6 the health problems and lives lost as a result of preterm births.

7 Globally, 14.9 million babies born preterm making a birth rate of 11.1%, ranging from 5%
8 to 18%, in 2010 (3). The majority (60%) of these births occurred in sub-Saharan Africa
9 and South Asia where 52% of global livebirths occur. The estimated global preterm birth
10 rate was also 10.6%, 14.84 million live preterm births, in 2014 (4). Twelve million (81.1%)
11 of these preterm births occurred in Asia and sub-Saharan Africa (4) showing the
12 contribution is raised from 2010. Ethiopia is one of the low-middle incomes countries in
13 Sub-Saharan Africa.

14 Preterm birth remains a crucial issue in child mortality and improving quality of maternal
15 and newborn care(4). Complications of preterm birth is the leading cause of death among
16 under 5 children with risk of dying ranged between 1.9 and 155.1 per 1,000 livebirths , in
17 2015 (5). In the same report, it had been found as the leading cause of death among
18 neonates contributing for 0.944 million deaths. Complication of infants born preterm
19 result in significant cost to the health sector, parents and the society in that preterm
20 neonates take the first place for neonatal intensive care unit (NICU) admission and longer
21 hospital stay globally (4).

22 Currently, WHO is committed to reduce the health problems and lives lost as a result of
23 preterm births (6). Hence, WHO had developed new guidelines including interventions

1 provided to the mother and the newborn baby (6). The Every Woman Every
2 Child movement is also aiming to intensify national and international commitment and
3 action to ensure that women, children and adolescents are at the heart of development.
4 The movement puts into action the global strategy (2016-2030) (7). The strategy is aimed
5 to end all preventable deaths of women, children and adolescents within a generation
6 and ensuring their well-being. Though Ethiopia achieved the millennium development
7 goal 4 with 67% under-five mortality reduction from the 1990 estimate, the reduction in
8 neonatal mortality is not remarkable (8). However, Ethiopia has planned to reduce
9 neonatal mortality rate from 28 in 2015/16 to 10 by 2019/2020 (9). Furthermore, the
10 country is also devoted to end preventable deaths of newborns and children under 5 years
11 of age by 2030 (10).

12 There are local studies on preterm births conducted in Ethiopia. The need for an accurate
13 and reliable result (11, 12), a single study aggregating these studies is necessary for
14 policy makers and implementers. Even though, there is a systematic review (13) done, it
15 addressed only the effect of pregnancy induced hypertension and multiple pregnancies
16 on preterm birth. However, literatures show that more factors affect preterm birth. Among
17 some of the identified associated factors of preterm birth in Ethiopia are obstetric
18 complication during the current pregnancy (14) specifically including pregnancy induced
19 hypertension (15, 16), premature rupture of membrane (17, 18) and hypertension during
20 pregnancy (17); history of obstetric complications including history of abortion (17), history
21 of still birth (17), history of low birth weight (17) and history of preterm birth (17); chronic
22 illness (15, 18), nutritional status (14), anemia (18), antenatal care follow up (14, 16, 18),
23 substance intake during pregnancy (17), multiple gestation (16, 17), and income status

1
2
3 1 (18). Hence, conducting a systematic review and meta-analysis on preterm birth is
4
5 2 paramount important in Ethiopia by updating the latest possible evidences.
6
7
8 3 Therefore this review is aimed at assessing the magnitude and associated factors of
9
10 4 preterm birth (births before 37 gestational weeks) in Ethiopia.

11 5 **METHODS AND ANALYSIS**

12 6 **Development of the review method**

13
14
15 7 The methods of this systematic review and meta-analysis protocol was developed based
16
17 8 on the PRISMA Protocols (PRISMA-P) 2015 statement (19). The preferred reporting
18
19 9 items for systematic reviews and meta-analyses (PRISMA) guideline will be followed
20
21 10 during the systematic review(20, 21). The result of the review will be reported according
22
23 11 to the PRISMA guideline for reporting (22). The four phases that were drawn from the
24
25 12 PRISMA flow chart (23) will be documented in the results to show the study selection
26
27 13 process from initially identified records to finally included studies. The protocol for this
28
29 14 systematic review and meta-analysis is registered in international prospective register of
30
31 15 systematic reviews (PROSPERO) and obtained the registration number
32
33 16 (CRD42017064585). The initial anticipated or actual start date as well as anticipated
34
35 17 completion date were updated with brief details on PROSPERO records. We would like
36
37 18 to disclose that the update was not related to any problem to the present study.

38 19 **Eligibility criteria**

39
40
41 20 We will include all observational studies that examined the level and/or associated factors
42
43 21 of preterm birth (births before 37 weeks of gestational period) in Ethiopia. Reviews,
44
45 22 editorials, case series and case reports on preterm birth as well as studies that only
46
47 23 reported qualitative findings on preterm birth will be excluded. In studies that reported
48
49
50
51
52
53
54
55
56
57
58
59
60

1 both quantitative and qualitative results, we will only consider the quantitative findings.
2 Studies will be considered relevant if they assessed the magnitude of preterm birth and/or
3 examined the associated factors of preterm birth. Regarding magnitude, only those
4 studies that reported percentages out of livebirths will be eligible.

5 **Search strategy**

6 Major medical electronic databases such as PubMed, and Science Direct will be searched
7 to identify relevant literature for the review. To cover grey literature, we will hand-search
8 literature using the Google search engine and Google Scholar and references of
9 electronically identified articles. Further, references list will also be considered from
10 relevant studies considered for critical appraisal.

11 The literature search will be carried out by the primary author (KFM). The search will be
12 limited to humans, and journal studies published in English from Jan 01, 2009 to Dec 31,
13 2019. We will apply Medical Subject Headings (MeSH) terms from PubMed, and
14 combined key words to identify studies in the databases.

15 Accordingly, literatures will be retrieved using the exact search phrase (*"Premature
16 Birth/epidemiology"[Mesh] OR "Premature Birth/etiology"[Mesh] OR "Premature
17 Birth/statistics and numerical data"[Mesh] OR premature birth* [MeSH] OR preterm birth
18 OR premature birth OR preterm labo* OR preterm deliver* OR preterm infant OR preterm
19 neonate* OR preterm newborn* OR birth outcome OR pregnancy outcome\$ OR
20 pregnancy complication\$ OR birth outcome\$ OR birth complication\$) AND Ethiopia AND
21 ((incidence OR prevalence OR magnitude OR burden) OR (predict* OR associated
22 factor* OR risk factor* OR determinant*)) from PubMed. This will be customized for other
23 databases.*

1 **Study selection process**

2 The retrieved studies will be exported to the citation manager (EndNote) and then
3 duplicates excluded. The titles and abstracts of the studies will be reviewed for screening
4 by two authors (KFM and AML) for obvious exclusion according to the eligibility/inclusion
5 criteria. Based on this screening, the titles and abstracts of the studies will be classified
6 as included, excluded, and undecided. Full text of all the included and the undecided
7 studies will be searched for further eligibility assessment.

8 The full texts of the included and undecided categories of the studies will be independently
9 reviewed by two authors (KFM and AML) against the eligibility criteria for final inclusion.

10 Studies that are not eligible based on the examination of the full-text will be excluded by
11 stating the reasons according to the inclusion criteria. Disagreements between the two
12 reviewers will be resolved through discussion and consensus.

13 Studies deemed to be appropriate will be scanned in full to determine relevance.

14 Secondly, the references lists of all relevant studies will be reviewed to find additional
15 studies that may have been difficult to detect in the database search due to non-reporting
16 in the abstract (possibly due to non-significant effects). Studies published by the same
17 team will be carefully reviewed to ensure the results of a given study are not included
18 twice in this review.

19 **Critical appraisal**

20 All of the included studies will be critically appraised for their validity. The three authors
21 (DFT, MKY, FA) will check the methodological robustness and validity of the findings
22 using the Joanna Briggs Institute (JBI) Meta-Analysis of Statistics Assessment and
23 Review Instrument (24). Uncertainties will be resolved by joint discussion between the

1 reviewers. Disagreements among the reviewers will be resolved through discussion and
2 consensus.

3 The JBI Meta-Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI)
4 will be used for critical appraisal (25). This tool contains a separate appraisal checklist for
5 each type of the study design. The reviewers will independently assess articles prior to
6 inclusion in the final review using this instrument. Any disagreement among the reviewers
7 will be resolved through discussion, and by involving another reviewer. A Study with
8 quality assessment score of 50% and above and a study having a response rate of 80%
9 and above were included in the final review.

10 **Data extraction**

11 The JBI data extraction form will be used to extract the characteristics of the studies and
12 prevalence of preterm birth (primary outcome) as well as Odds ratio (secondary
13 outcomes). A standardized excel sheet will be created and information from the
14 standardized review forms will be transferred in order to be readily available for the
15 systematic review. Three reviewers (KFM, MMS and AML) will extract data
16 independently. Disagreements among the reviewers were resolved through discussion
17 and consensus.

18 This tool will include information on the author, year of publication, objective, study
19 setting, year of survey, study design, sample size, data collection method, study
20 participants, definition used for preterm birth, prevalence of preterm, 95% CI for
21 prevalence of preterm birth, and list of associated factors with their effect size. A
22 quantitative data of cross-tabulation between the subject's characteristics (associated
23 factors) and the preterm birth will also systematically abstracted.

1 **Data synthesis and statistical analysis**

2 The individual studies will be concisely described using a summary table. The summary
3 table particularly describes the characteristics of the included studies and the main
4 findings.

5 The data will be analyzed by the Stata software version 14. For studies which did not
6 present a standard error (SE), it will be calculated using the formula; $SE = \sqrt{(p \times (1-p)/n)}$.

7 The calculated standard error and prevalence rate of each study will then entered into

8 Stata software to calculate the overall prevalence and its 95% confidence interval (CI).

9 Similarly, the relationship between factors and preterm birth will be summarized using

10 statistical estimates of effect sizes, odds ratio. Subgroup analysis will be sought based

11 on possible characteristics of the studies.

12 The level of heterogeneity among the studies will be quantified using the I^2 statistics (26).

13 Meta-analysis using random effects model will be conducted for the I^2 value of more than

14 75%, considered as heterogeneity. Publication bias will be assessed using a funnel plot

15 and Egger's test of small study bias. Symmetric funnel plot as well as insignificant Egger's

16 test will be taken as evidence for no serious small study bias (publication bias). Trim and

17 fill technique will be considered for substantial publication bias. Further, sensitivity

18 analysis will be used to assess the influential studies on the pooled estimate.

19 Forest plots will be used to present the combined estimate with 95% CI. The quality of evidence

20 of the outcomes will be assessed with the GRADE approach. If no more than one study

21 will be found for each of the objective, then the finding will be synthesized narratively.

22 **Potential limitations**

1
2
3 1 Only quantitative observational studies published in English will be included. This might
4
5 2 exclude studies those published in other languages. Further, qualitative studies that
6
7 3 assessed the associated factors might be excluded. Therefore, the readers are advised
8
9 4 to take this into account.
10
11
12

13 **Patient and public involvement**

14
15 6 It was not appropriate to involve patients or the public in the design, or conduct, or
16
17 7 reporting, or dissemination plans of our research as no individual information will be
18
19 8 discussed.
20
21

22 **Ethics and dissemination**

23
24 10 The review will be based on published data, and thus there is no requirement for ethical
25
26 11 approval. The results will be disseminated through publication in a peer reviewed journal,
27
28 12 and through presentations at academic conferences.
29
30

31 **DISCUSSION**

32
33 14 It is crucial to know the importance of preterm birth and contributing factors considering
34
35 15 the latest statistics in a country. Hence, this review will present on the country wide
36
37 16 magnitude of preterm birth and the associated factors of preterm birth. The result will
38
39 17 provide information to guide health professionals and health policy makers for monitoring
40
41 18 preterm birth strategy and applying necessary preventive and appropriate measures to
42
43 19 decrease preterm birth.
44
45
46

47 **Abbreviations**

48
49 21 ACTION: Antenatal Corticosteroids for Improving Outcomes in preterm Newborns
50

51
52 22 CI: Confidence Interval
53

54
55 23 JBI: Joanna Briggs Institute
56
57
58
59
60

1
2
3 1 JBI-MAStARI: JBI Meta-Analysis of Statistics Assessment and Review Instrument

4
5 2 KMC: Kangaroo Mother Care

6
7 3 LMICs: Low and Middle Income Countries

8
9 4 MeSH: Medical Subject Headings

10
11 5 NICU: Neonatal Intensive Care Unit

12
13 6 NMR: Neonatal Mortality Rate

14
15 7 PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analyses

16
17 8 PRISMA-P: Preferred Reporting Items for Systematic Reviews and Meta-analyses

18
19 9 Protocol

20
21 10 PROSPERO: Prospective Register of Systematic Reviews

22
23 11 SE: Standard Error

24
25 12 WHO: World Health Organization

26
27 13 **Declarations**

28
29 14 ***Consent for publication***

30
31 15 Not applicable.

32
33 16 ***Availability of data and materials***

34
35 17 Not applicable.

36
37 18 ***Competing interests***

38
39 19 The authors declare that they have no competing interests

40
41 20 ***Funding***

42
43 21 None.

1 **Author contributions**

2 KFM, MKY, YAH contributed to the conception of the research protocol. KFM, AML, DFT,
3 MMS, FAM designed the study. KFM, DFT, AML reviewed the literature, and wrote the
4 protocol. KFM, AML, DFT, MKY, FAM, MMS, and YAH reviewed and rewrote the protocol.
5 All authors read and approved the final manuscript.

6 **References**

- 7 1. Who: Recommended Definitions, Terminology and Format for Statistical Tables Related
8 to The Perinatal Period And Use of A New Certificate For Cause of Perinatal Deaths. *Acta*
9 *Obstetrica et Gynecologica Scandinavica*. 1977;56(3):247-53.
- 10 2. March of Dimes, PMNCH, Save the Children, WHO. Born Too Soon: The Global action
11 report on preterm Birth. In: Eds CP Howson, MV Kinney, JE Lawn, editors. Geneva: World
12 Health Organization; 2012.
- 13 3. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller A-B, Narwal R, et al.
14 National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time
15 trends since 1990 for selected countries: a systematic analysis and implications. *The Lancet*.
16 2012;379(9832):2162-72.
- 17 4. Chawanpaiboon S, Vogel JP, Moller A-B, Lumbiganon P, Petzold M, Hogan D, et al.
18 Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review
19 and modelling analysis. *The Lancet Global Health*. 2019;7(1):e37-e46.
- 20 5. Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, et al. Global, regional, and national
21 causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the
22 Sustainable Development Goals. *The Lancet*. 2016;388(10063):3027-35.
- 23 6. WHO. WHO Fact sheets on Preterm birth In: WHO, editor. 2018.
- 24 7. Every Woman Every Child. The global strategy for women's, children's, and adolescents'
25 health (2016-2030): Survive, thrive, transform. In: Every Woman Every Child, editor. 2015.
- 26 8. Ruducha J, Mann C, Singh NS, Gemebo TD, Tessema NS, Baschieri A, et al. How
27 Ethiopia achieved Millennium Development Goal 4 through multisectoral interventions: a
28 Countdown to 2015 case study. *The Lancet Global Health*. 2017;5(11):e1142-e51.
- 29 9. The Federal Democratic Republic of Ethiopia Ministry of Health. Health Sector
30 Transformation Plan. 2015.
- 31 10. United Nations. Sustainable Development Goals. Secretary-General. 2015.
- 32 11. Cohn LD, Becker BJ. How meta-analysis increases statistical power. *Psychological*
33 *Methods*. 2003;8(3):243-53.
- 34 12. Noble JH, Jr. Meta-analysis: Methods, strengths, weaknesses, and political uses. *The*
35 *Journal of Laboratory and Clinical Medicine*. 2006;147(1):7-20.
- 36 13. Mulualem G, Wondim A, Woretaw A. The effect of pregnancy induced hypertension and
37 multiple pregnancies on preterm birth in Ethiopia: a systematic review and meta-analysis. *BMC*
38 *Research Notes*. 2019;12(1):91.
- 39 14. Mekonen DG, Yismaw AE, Nigussie TS, Ambaw WM. Proportion of Preterm birth and
40 associated factors among mothers who gave birth in Debretabor town health institutions,
41 northwest, Ethiopia. *BMC Research Notes*. 2019;12(1):2.
- 42 15. Gebreslasie K. Preterm Birth and Associated Factors among Mothers Who Gave Birth in
43 Gondar Town Health Institutions. *Advances in Nursing*. 2016;2016.

- 1
2
3 1 16. Teklay G, Teshale T, Tasew H, Mariye T, Berihu H, Zeru T. Risk factors of preterm birth
4 2 among mothers who gave birth in public hospitals of central zone, Tigray, Ethiopia: unmatched
5 3 case-control study 2017/2018. *BMC Research Notes*. 2018;11(1):571.
6 4 17. Bekele I, Demeke T, Dugna K. Prevalence of Preterm Birth and its Associated Factors
7 5 among Mothers Delivered in Jimma University Specialized Teaching and Referral Hospital,
8 6 Jimma Zone, Oromia Regional State, South West Ethiopia. *Journal of Women's Health Care*.
9 7 2017;6(1).
10 8 18. Bekele T, Amanon A, Gebreslasie KZ. Preterm birth and associated factors among
11 9 mothers who gave birth in Debremarkos-town health institutions 2013 institutional
12 10 based cross-sectional study. *Gynecology & Obstetrics (Sunnyvale)* 2015;5(5).
13 11 19. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred
14 12 reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
15 13 *Systematic Reviews*. 2015;4(1).
16 14 20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic
17 15 reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151.
18 16 21. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Reprint—preferred reporting items
19 17 for systematic reviews and meta-analyses: the PRISMA statement. *Physical therapy*.
20 18 2009;89(9):873-80.
21 19 22. Beller E, Glasziou P, Altman D, Hopewell S, Bastian H, Chalmers I, et al. PRISMA for
22 20 abstracts: reporting systematic reviews in journal and conference abstracts. *PLoS Med*.
23 21 2013;10(4).
24 22 23. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic
25 23 reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7).
26 24 24. Joanna Briggs institute Reviewers' manual 2014 edition. Adelaide: Adelaide University;
27 25 2014.
28 26 25. Joanna Briggs institute reviewers' manual 2008.
29 27 26. Higgins J, Hompson S. Quantifying heterogeneity in a meta-analysis 2002.

28

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

| Section and topic | Item No | Checklist item | (Page No.#) |
|-----------------------------------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| ADMINISTRATIVE INFORMATION | | | |
| Title: | | | |
| Identification | 1a | Identify the report as a protocol of a systematic review | 1 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | NA |
| Registration | 2 | If registered, provide the name of the registry (such as PROSPERO) and registration number | 2, 6 |
| Authors: | | | |
| Contact | 3a | Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author | 1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | 13 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | NA |
| Support: | | | |
| Sources | 5a | Indicate sources of financial or other support for the review | 12 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | NA |
| Role of sponsor or funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | NA |
| INTRODUCTION | | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | 4-6 |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | 6 |
| METHODS | | | |
| Eligibility criteria | 8 | Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review | 6-7 |
| Information sources | 9 | Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage | 7 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | 7 |

| | | | |
|------------------------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| Study records: | | | |
| Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | 6-10 |
| Selection process | 11b | State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) | 8-9 |
| Data collection process | 11c | Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | 9 |
| Data items | 12 | List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications | 9 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | 9 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | 8-10 |
| Data synthesis | 15a | Describe criteria under which study data will be quantitatively synthesised | 10 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I ² , Kendall's τ) | 10 |
| | 15c | Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) | 10 |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned | 10 |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) | 10 |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (such as GRADE) | 10 |

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

BMJ Open

The prevalence and associated factors of preterm birth in Ethiopia: Systematic review and meta-analysis protocol

| | |
|---------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Journal: | <i>BMJ Open</i> |
| Manuscript ID | bmjopen-2019-035574.R2 |
| Article Type: | Protocol |
| Date Submitted by the Author: | 11-Mar-2020 |
| Complete List of Authors: | Muchie, Kindie Fentahun; Bahir Dar University, Epidemiology and Biostatistics Molla, Ayenew; University of Gondar College of Medicine and Health Sciences, Epidemiology and Biostatistics; Teshome, Destaw; University of Gondar College of Medicine and Health Sciences, Epidemiology and Biostatistics Yenit, Melaku; University of Gondar, Epidemiology and Biostatistics Sisay, Malede; University of Gondar College of Medicine and Health Sciences, Epidemiology and Biostatistics Mekonnen, Fantahun Ayenew ; University of Gondar, Epidemiology and Biostatistics Habitu, Yohanes Ayanaw; University of Gondar, Reproductive Health |
| Primary Subject Heading: | Public health |
| Secondary Subject Heading: | Public health, Global health |
| Keywords: | PUBLIC HEALTH, NEONATOLOGY, GYNAECOLOGY, OBSTETRICS |
| | |

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The prevalence and associated factors of preterm birth in Ethiopia: Systematic review and meta-analysis protocol

Kindie Fentahun Muchie^{1*}, Ayenew Molla Lakew², Destaw Fetene Teshome², Melaku Kindie Yenit², Malede Mequanent Sisay², Fantahun Ayenew Mekonnen², Yohanes Ayanaw Habitu³

¹Department of Epidemiology and Biostatistics, School of Public Health, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia

²Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

³Department of Reproductive Health, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

E-mail addresses:

KFM (mkindief@gmail.com), AML (mayenew15@gmail.com), DFT
(destaw.fetene@gmail.com), MKY (melaku98@gmail.com), MMS
(maledecsa@gmail.com), FAM (fantahun.ayenew@yahoo.com), YAH
(ayanawyohanes@yahoo.com)

*Correspondence

ABSTRACT

Introduction: Preterm birth (PTB) complications are the leading cause of death among neonates globally. The reduction in neonatal mortality is not remarkable in Ethiopia. Therefore, this review will assess the magnitude and associated factors of PTB in Ethiopia.

Methods and Analysis: The preferred reporting items for systematic reviews and meta-analyses guideline will be followed during the systematic review. We will include all observational studies published from Jan 01, 2009 to Dec 31, 2019 that examined the level and/or associated factors of any type of PTB among livebirths in Ethiopia. Inclusion criteria will be all livebirths, PTB defined as delivery before 37 weeks' gestation. The primary outcome will be PTB < 37 weeks, and secondary outcomes including PTB < 34, < 32 and <28 weeks will be analyzed. PubMed, and Science Direct databases as well as Google search engine and Google Scholar will be searched. The pooled prevalence of preterm and effect size of association for associated factors will be analyzed using the Stata software version 14. The heterogeneity between studies will be measured by I^2 statistics. A random-effects model will be used to estimate if heterogeneity detected. Publication bias will be assessed using a funnel plot. Subgroup analysis will be sought based on possible characteristics of the studies, specific morbidity (like pre-eclampsia, hypertension), type of PTB (spontaneous or iotrogenic), and quality of study (high quality or low risk). Meta-regression will be considered for major covariates (maternal age and maternal body mass index) related to PTB. Forest plots will be used to present the combined estimate with 95% confidence intervals. The quality of evidence of the outcomes will be assessed with the GRADE approach.

1
2
3 **Ethics and dissemination:** No ethical approval is necessary for this systematic review.
4

5 The findings will be published in a peer-reviewed journal.
6

7 **PROSPERO registration number:** CRD42017077356.
8

9
10 **Keywords:** Preterm birth, Prevalence, Associated Factors, Ethiopia, Systematic review,
11
12 Meta-analysis
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STRENGTHS AND LIMITATIONS OF THIS STUDY

- The proposed study will provide updated knowledge on the prevalence of preterm birth, leading cause of neonatal death, in Ethiopia where reduction in neonatal mortality is no remarkable.
- The proposed study will provide a comprehensive knowledge on the associated factors of preterm birth in Ethiopia.
- The PRISMA guideline will be followed during the proposed systematic review.
- Standard tool for critical appraisal and data extraction will be used
- Only quantitative observational studies published in English will be included.

INTRODUCTION

Preterm birth (PTB) is a birth before 37 completed weeks of gestation (1). It is more prevalent in Africa and Asia. PTB complications remained the leading cause of under-5 and neonatal mortalities. PTB, the majority being spontaneously, occurs for a variety of reasons(2). Currently, World Health Organization (WHO) is committed to reduce the health problems and lives lost as a result of preterm births.

Globally, 14.9 million babies born preterm making a birth rate of 11.1%, ranging from 5% to 18%, in 2010 (3). The majority (60%) of these births occurred in sub-Saharan Africa and South Asia where 52% of global livebirths occur. The estimated global PTB rate was also 10.6%, 14.84 million live PTBs, in 2014 (4). Twelve million (81.1%) of these PTBs occurred in Asia and sub-Saharan Africa (4) showing the contribution is raised from 2010. Ethiopia is one of the low-middle incomes countries in Sub-Saharan Africa.

Preterm birth remains a crucial issue in child mortality and improving quality of maternal and newborn care(4). Complications of PTB is the leading cause of death among under 5 children with risk of dying ranged between 1.9 and 155.1 per 1,000 livebirths , in 2015 (5). In the same report, it had been found as the leading cause of death among neonates contributing for 0.944 million deaths. Complication of infants born preterm result in significant cost to the health sector, parents and the society in that preterm neonates take the first place for neonatal intensive care unit (NICU) admission and longer hospital stay globally (4).

Currently, WHO is committed to reduce the health problems and lives lost as a result of PTBs (6). Hence, WHO had developed new guidelines including interventions provided to the mother and the newborn baby (6). The Every Woman Every Child movement is

1
2
3 also aiming to intensify national and international commitment and action to ensure that
4 women, children and adolescents are at the heart of development. The movement puts
5 into action the global strategy (2016-2030) (7). The strategy is aimed to end all
6 preventable deaths of women, children and adolescents within a generation and ensuring
7 their well-being. Though Ethiopia achieved the millennium development goal 4 with 67%
8 under-five mortality reduction from the 1990 estimate, the reduction in neonatal mortality
9 is not remarkable (8). However, Ethiopia has planned to reduce neonatal mortality rate
10 from 28 in 2015/16 to 10 by 2019/2020 (9). Furthermore, the country is also devoted to
11 end preventable deaths of newborns and children under 5 years of age by 2030 (10).

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
There are local studies on PTBs conducted in Ethiopia. The need for an accurate and
reliable result (11, 12), a single study aggregating these studies is necessary for policy
makers and implementers. Even though, there is a systematic review (13) done, it
addressed only the effect of pregnancy induced hypertension and multiple pregnancies
on preterm birth. However, literatures show that more factors affect PTB. Among some
of the identified associated factors of PTB in Ethiopia are obstetric complication during
the current pregnancy (14) specifically including pregnancy induced hypertension (15,
16), premature rupture of membrane (17, 18) and hypertension during pregnancy (17);
history of obstetric complications including history of abortion (17), history of still birth
(17), history of low birth weight (17) and history of PTB (17); chronic illness (15, 18),
nutritional status (14), anemia (18), antenatal care follow up (14, 16, 18), substance intake
during pregnancy (17), multiple gestation (16, 17), and income status (18). Hence,
conducting a systematic review and meta-analysis on PTB is paramount important in
Ethiopia by updating the latest possible evidences.

1
2
3 Therefore this review is aimed at assessing the magnitude and associated factors of PTB
4
5 in Ethiopia.
6

7 **METHODS AND ANALYSIS**

8 **Development of the review method**

9
10 The methods of this systematic review and meta-analysis protocol was developed based
11
12 on the PRISMA Protocols (PRISMA-P) 2015 statement (19). The preferred reporting
13
14 items for systematic reviews and meta-analyses (PRISMA) guideline will be followed
15
16 during the systematic review(20, 21). The result of the review will be reported according
17
18 to the PRISMA guideline for reporting (22). The four phases that were drawn from the
19
20 PRISMA flow chart (23) will be documented in the results to show the study selection
21
22 process from initially identified records to finally included studies. The protocol for this
23
24 systematic review and meta-analysis is registered in international prospective register of
25
26 systematic reviews (PROSPERO) and obtained the registration number
27
28 (CRD42017064585). The initial anticipated or actual start date as well as anticipated
29
30 completion date were updated with brief details on PROSPERO records. We would like
31
32 to disclose that the update was not related to any problem to the present study.
33
34
35
36
37
38
39

40 **Eligibility criteria**

41
42 We will include all observational studies that examined the level and/or associated factors
43
44 of any type of PTB among livebirths in Ethiopia. Inclusion criteria will be all livebirths, PTB
45
46 defined as delivery before 37 weeks' gestation. The primary outcome will be PTB, with
47
48 PTB defined as a delivery occurring before 37 completed weeks of gestation. Other
49
50 relevant secondary outcomes to PTB will be considered including PTB < 34, < 32 or < 28
51
52 weeks. Reviews, editorials, case series and case reports on PTB as well as studies that
53
54
55
56
57
58
59
60

1
2
3 only reported qualitative findings on PTB will be excluded. In studies that reported both
4 quantitative and qualitative results, we will only consider the quantitative findings. Studies
5 will be considered relevant if they assessed the magnitude of PTB and/or examined the
6 associated factors of preterm birth. Regarding magnitude, only those studies that reported
7 percentages out of livebirths will be eligible.
8
9
10
11
12
13

14 **Search strategy**

15 Major medical electronic databases such as PubMed, and Science Direct will be searched
16 to identify relevant literature for the review. To cover grey literature, we will hand-search
17 literature using the Google search engine and Google Scholar and references of
18 electronically identified articles. Further, references list will also be considered from
19 relevant studies considered for critical appraisal.
20
21
22
23
24
25
26

27 The literature search will be carried out by the primary author (KFM). The search will be
28 limited to humans, and journal studies published in English from Jan 01, 2009 to Dec 31,
29 2019. We will apply Medical Subject Headings (MeSH) terms from PubMed, and
30 combined key words to identify studies in the databases.
31
32
33
34
35
36

37 Accordingly, literatures will be retrieved using the exact search phrase (*"Premature
38 Birth/epidemiology"[Mesh] OR "Premature Birth/etiology"[Mesh] OR "Premature
39 Birth/statistics and numerical data"[Mesh] OR premature birth* [MeSH] OR preterm birth
40 OR premature birth OR preterm labo* OR preterm deliver* OR preterm infant OR preterm
41 neonate* OR preterm newborn* OR birth outcome OR pregnancy outcome\$ OR
42 pregnancy complication\$ OR birth outcome\$ OR birth complication\$) AND Ethiopia AND
43 ((incidence OR prevalence OR magnitude OR burden) OR (predict* OR associated
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60*

1
2
3 *factor* OR risk factor* OR determinant*))* from PubMed. This will be customized for other
4
5 databases.

8 **Study selection process**

9
10 The retrieved studies will be exported to the citation manager (EndNote) and then
11
12 duplicates excluded. The titles and abstracts of the studies will be reviewed for screening
13
14 by two authors (KFM and AML) for obvious exclusion according to the eligibility/inclusion
15
16 criteria. Based on this screening, the titles and abstracts of the studies will be classified
17
18 as included, excluded, and undecided. Full text of all the included and the undecided
19
20 studies will be searched for further eligibility assessment.

21
22
23 The full texts of the included and undecided categories of the studies will be independently
24
25 reviewed by two authors (KFM and AML) against the eligibility criteria for final inclusion.
26
27 Studies that are not eligible based on the examination of the full-text will be excluded by
28
29 stating the reasons according to the inclusion criteria. Disagreements between the two
30
31 reviewers will be resolved through discussion and consensus.

32
33
34 Studies deemed to be appropriate will be scanned in full to determine relevance.
35
36 Secondly, the references lists of all relevant studies will be reviewed to find additional
37
38 studies that may have been difficult to detect in the database search due to non-reporting
39
40 in the abstract (possibly due to non-significant effects). Studies published by the same
41
42 team will be carefully reviewed to ensure the results of a given study are not included
43
44 twice in this review.

48 **Critical appraisal**

49
50 All of the included studies will be critically appraised for their validity. The three authors
51
52 (DFT, MKY, FA) will check the methodological robustness and validity of the findings
53
54

1
2
3 using the Joanna Briggs Institute (JBI) Meta-Analysis of Statistics Assessment and
4 Review Instrument (24). Uncertainties will be resolved by joint discussion between the
5 reviewers. Disagreements among the reviewers will be resolved through discussion and
6 consensus.
7
8
9

10
11
12 The JBI Meta-Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI)
13 will be used for critical appraisal (25). This tool contains a separate appraisal checklist for
14 each type of the study design. The reviewers will independently assess articles prior to
15 inclusion in the final review using this instrument. Any disagreement among the reviewers
16 will be resolved through discussion, and by involving another reviewer. A Study with
17 quality assessment score of 50% and above and a study having a response rate of 80%
18 and above were included in the final review.
19
20
21
22
23
24
25
26
27

28 **Data extraction**

29
30
31 The JBI data extraction form will be used to extract the characteristics of the studies and
32 prevalence of preterm birth (primary outcome and secondary outcomes) as well as Odds
33 ratio. A standardized excel sheet will be created and information from the standardized
34 review forms will be transferred in order to be readily available for the systematic review.
35
36
37
38
39
40 Three reviewers (KFM, MMS and AML) will extract data independently. Disagreements
41 among the reviewers were resolved through discussion and consensus.
42
43

44
45 This tool will include information on the author, year of publication, objective, study
46 setting, year of survey, study design, sample size, data collection method, study
47 participants, definition used for preterm birth, prevalence of preterm, 95% CI for
48 prevalence of preterm birth, and list of associated factors with their effect size. A
49
50
51
52
53
54
55
56
57

1
2
3 quantitative data of cross-tabulation between the subject's characteristics (associated
4 factors) and the preterm birth will also systematically abstracted.
5
6

7 **Data synthesis and statistical analysis**

8
9
10 The individual studies will be concisely described using a summary table. The summary
11 table particularly describes the characteristics of the included studies and the main
12 findings.
13
14
15

16
17 The data will be analyzed by the Stata software version 14. For studies which did not
18 present a standard error (SE), it will be calculated using the formula; $SE = \sqrt{(p \times (1-p)/n)}$.
19

20
21 The calculated standard error and prevalence rate of each study will then entered into
22 Stata software to calculate the overall prevalence and its 95% confidence interval (CI).
23
24

25
26 Similarly, the relationship between factors and preterm birth will be summarized using
27 statistical estimates of effect sizes, odds ratio. Subgroup analysis will be sought based
28 on possible characteristics of the studies, specific morbidity (like pre-eclampsia,
29 hypertension), type of PTB (spontaneous or iotrogenic), and quality of study (high quality
30 or low risk). Meta-regression will be considered for major covariates (maternal age and
31 maternal body mass index) related to PTB. Meta-regression will be considered for major
32 covariates (maternal age and maternal body mass index) related to PTB.
33
34
35
36
37
38
39
40
41

42 The level of heterogeneity among the studies will be quantified using the I^2 statistics (26).
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 fill technique will be considered for substantial publication bias. Further, sensitivity
4
5 analysis will be used to assess the influential studies on the pooled estimate.
6

7
8 Forest plots will be used to present the combined estimate with 95% CI. The quality of evidence
9
10 of the outcomes will be assessed with the GRADE approach. If no more than one study
11
12 will be found for each of the objective, then the finding will be synthesized narratively.
13

14 **Potential limitations**

15
16 Only quantitative observational studies published in English will be included. This might
17
18 exclude studies those published in other languages. Further, qualitative studies that
19
20 assessed the associated factors might be excluded. Therefore, the readers are advised
21
22 to take this into account.
23
24

25 **Patient and public involvement**

26
27 It was not appropriate to involve patients or the public in the design, or conduct, or
28
29 reporting, or dissemination plans of our research as no individual information will be
30
31 discussed.
32
33

34 **Ethics and dissemination**

35
36 The review will be based on published data, and thus there is no requirement for ethical
37
38 approval. The results will be disseminated through publication in a peer reviewed journal,
39
40 and through presentations at academic conferences.
41
42

43 **DISCUSSION**

44
45 It is crucial to know the importance of preterm birth and contributing factors considering
46
47 the latest statistics in a country. Hence, this review will present on the country wide
48
49 magnitude of preterm birth and the associated factors of preterm birth. The result will
50
51 provide information to guide health professionals and health policy makers for monitoring
52
53
54
55
56
57

1
2
3 preterm birth strategy and applying necessary preventive and appropriate measures to
4
5 decrease preterm birth.
6

7 **Abbreviations**

8
9
10 ACTION: Antenatal Corticosteroids for Improving Outcomes in preterm Newborns

11
12 CI: Confidence Interval

13
14 JBI: Joanna Briggs Institute

15
16 JBI-MAStARI: JBI Meta-Analysis of Statistics Assessment and Review Instrument

17
18 KMC: Kangaroo Mother Care

19
20 LMICs: Low and Middle Income Countries

21
22 MeSH: Medical Subject Headings

23
24 NICU: Neonatal Intensive Care Unit

25
26 NMR: Neonatal Mortality Rate

27
28 PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analyses

29
30 PRISMA-P: Preferred Reporting Items for Systematic Reviews and Meta-analyses

31
32 Protocol

33
34 PROSPERO: Prospective Register of Systematic Reviews

35
36 PTB: Preterm Birth

37
38 SE: Standard Error

39
40 WHO: World Health Organization

41 **Declarations**

42 ***Consent for publication***

43
44 Not applicable.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Availability of data and materials

Not applicable.

Competing interests

The authors declare that they have no competing interests

Funding

None.

Author contributions

KFM, MKY, YAH contributed to the conception of the research protocol. KFM, AML, DFT, MMS, FAM designed the study. KFM, DFT, AML reviewed the literature, and wrote the protocol. KFM, AML, DFT, MKY, FAM, MMS, and YAH reviewed and rewrote the protocol.

All authors read and approved the final manuscript.

References

1. Who: Recommended Definitions, Terminology and Format for Statistical Tables Related to The Perinatal Period And Use of A New Certificate For Cause of Perinatal Deaths. *Acta Obstetricia et Gynecologica Scandinavica*. 1977;56(3):247-53.
2. March of Dimes, PMNCH, Save the Children, WHO. Born Too Soon: The Global action report on preterm Birth. In: Eds CP Howson, MV Kinney, JE Lawn, editors. Geneva: World Health Organization; 2012.
3. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller A-B, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. *The Lancet*. 2012;379(9832):2162-72.
4. Chawanpaiboon S, Vogel JP, Moller A-B, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. *The Lancet Global Health*. 2019;7(1):e37-e46.
5. Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. *The Lancet*. 2016;388(10063):3027-35.
6. WHO. WHO Fact sheets on Preterm birth In: WHO, editor. 2018.
7. Every Woman Every Child. The global strategy for women's, children's, and adolescents' health (2016-2030): Survive, thrive, transform. In: Every Woman Every Child, editor. 2015.
8. Ruducha J, Mann C, Singh NS, Gemebo TD, Tessema NS, Baschieri A, et al. How Ethiopia achieved Millennium Development Goal 4 through multisectoral interventions: a Countdown to 2015 case study. *The Lancet Global Health*. 2017;5(11):e1142-e51.
9. The Federal Democratic Republic of Ethiopia Ministry of Health. Health Sector Transformation Plan. 2015.
10. United Nations. Sustainable Development Goals. Secretary-General. 2015.

11. Cohn LD, Becker BJ. How meta-analysis increases statistical power. *Psychological Methods*. 2003;8(3):243-53.
12. Noble JH, Jr. Meta-analysis: Methods, strengths, weaknesses, and political uses. *The Journal of Laboratory and Clinical Medicine*. 2006;147(1):7-20.
13. Muluaem G, Wondim A, Woretaw A. The effect of pregnancy induced hypertension and multiple pregnancies on preterm birth in Ethiopia: a systematic review and meta-analysis. *BMC Research Notes*. 2019;12(1):91.
14. Mekonen DG, Yismaw AE, Nigussie TS, Ambaw WM. Proportion of Preterm birth and associated factors among mothers who gave birth in Debretabor town health institutions, northwest, Ethiopia. *BMC Research Notes*. 2019;12(1):2.
15. Gebreslasie K. Preterm Birth and Associated Factors among Mothers Who Gave Birth in Gondar Town Health Institutions. *Advances in Nursing*. 2016;2016.
16. Teklay G, Teshale T, Tasew H, Mariye T, Berihu H, Zeru T. Risk factors of preterm birth among mothers who gave birth in public hospitals of central zone, Tigray, Ethiopia: unmatched case-control study 2017/2018. *BMC Research Notes*. 2018;11(1):571.
17. Bekele I, Demeke T, Dugna K. Prevalence of Preterm Birth and its Associated Factors among Mothers Delivered in Jimma University Specialized Teaching and Referral Hospital, Jimma Zone, Oromia Regional State, South West Ethiopia. *Journal of Women's Health Care*. 2017;6(1).
18. Bekele T, Amanon A, Gebreslasie KZ. Preterm birth and associated factors among mothers who gave birth in Debremarkos-town health institutions 2013 institutional based cross-sectional study. *Gynecology & Obstetrics (Sunnyvale)* 2015;5(5).
19. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews*. 2015;4(1).
20. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009;151.
21. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Reprint—preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Physical therapy*. 2009;89(9):873-80.
22. Beller E, Glasziou P, Altman D, Hopewell S, Bastian H, Chalmers I, et al. PRISMA for abstracts: reporting systematic reviews in journal and conference abstracts. *PLoS Med*. 2013;10(4).
23. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7).
24. Joanna Briggs institute Reviewers' manual 2014 edition. Adelaide: Adelaide University; 2014.
25. Joanna Briggs institute reviewers' manual 2008.
26. Higgins J, Hompson S. Quantifying heterogeneity in a meta-analysis 2002.

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

| Section and topic | Item No | Checklist item | (Page No.#) |
|-----------------------------------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| ADMINISTRATIVE INFORMATION | | | |
| Title: | | | |
| Identification | 1a | Identify the report as a protocol of a systematic review | 1 |
| Update | 1b | If the protocol is for an update of a previous systematic review, identify as such | NA |
| Registration | 2 | If registered, provide the name of the registry (such as PROSPERO) and registration number | 3, 7 |
| Authors: | | | |
| Contact | 3a | Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author | 1 |
| Contributions | 3b | Describe contributions of protocol authors and identify the guarantor of the review | 14 |
| Amendments | 4 | If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments | NA |
| Support: | | | |
| Sources | 5a | Indicate sources of financial or other support for the review | 14 |
| Sponsor | 5b | Provide name for the review funder and/or sponsor | NA |
| Role of sponsor or funder | 5c | Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol | NA |
| INTRODUCTION | | | |
| Rationale | 6 | Describe the rationale for the review in the context of what is already known | 5-6 |
| Objectives | 7 | Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) | 7 |
| METHODS | | | |
| Eligibility criteria | 8 | Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review | 7-8 |
| Information sources | 9 | Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage | 8 |
| Search strategy | 10 | Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated | 8-9 |

| | | | |
|------------------------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|
| Study records: | | | |
| Data management | 11a | Describe the mechanism(s) that will be used to manage records and data throughout the review | 6-10 |
| Selection process | 11b | State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) | 7-10 |
| Data collection process | 11c | Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators | 10-11 |
| Data items | 12 | List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications | 10-11 |
| Outcomes and prioritization | 13 | List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale | 7 |
| Risk of bias in individual studies | 14 | Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis | 11-12 |
| Data synthesis | 15a | Describe criteria under which study data will be quantitatively synthesised | 12 |
| | 15b | If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ) | 11-12 |
| | 15c | Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) | 11-12 |
| | 15d | If quantitative synthesis is not appropriate, describe the type of summary planned | 12 |
| Meta-bias(es) | 16 | Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) | 11-12 |
| Confidence in cumulative evidence | 17 | Describe how the strength of the body of evidence will be assessed (such as GRADE) | 12 |

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.